Coherus Oncology, Inc. (CHRS) Form 8-K — Aug 17, 2026
On August 12, 2026, Coherus Oncology entered into a Loan and Security Agreement with Innovatus Life Sciences Lending Fund I, LP as collateral agent, providing a $55.0 million senior secured term loan (Tranche A) maturing in August 2031. The company drew the full amount on August 14, 2026 and used a portion to repay its prior secured facility in full. The new facility accrues interest at 4.15% over the greater of the Prime Rate or 6.75%, carries a 1.50% facility fee, and requires interest-only payments for 36 months, extendable to 48 months if revenue and market capitalization milestones are met.
Key figures
- Debt Amount
- 55000000
- Interest Rate
- Floating: 4.15% plus the greater of the Prime Rate or 6.75%
- Maturity Date
- August 2031
- Final Fee
- 4.00% of funded principal, rising to 10.00% if insolvency proceeds with DIP financing
- Facility Fee
- 1.50% of funded principal on each funding date
- Funding Date
- 2026-08-14
- Prior Loan Rate
- 8.0% plus three-month SOFR
- Prepayment Fees
- 5.00% through year 1 (plus make-whole interest), 4.00% year 2, 3.00% year 3, 0.00% thereafter
- Optional Tranche B
- 25000000
- Optional Tranche C
- 20000000
- Tranche ATerm Loan
- 55000000
- Prior Loan Maturity
- May 2029
- Interest Only Period
- 36 months, extendable to 48 months upon achieving revenue and market capitalization milestones
- Optional Tranche CCondition
- lender sole discretion
- Optional Tranche CMilestone
- milestone-based
Price after filing
Close on the filing date to close N calendar days later (from $1.15). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.